Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Long Term Safety - number of patients experiencing any adverse event
Listing of adverse event rate in patients receiving L-BLP25 only.
Time from first dose up to 30 days after last dose of study treatment with L-BLP25 reported between day of first patient enrolled
United States: Food and Drug Administration
|US Medical Information located in||Rockland, Massachusetts|